You are here: Industry Insights > Spark Therapeutics

News List

NeuExcell Therapeutics and Spark Therapeutics Announce Research Collaboration Agreement to Develop a Novel Gene Therapy for Huntington's Disease prnasia
September 13, 2021
OTCQX: RHHBY) today announced a gene therapy collaboration aimed at developing a safe and effective treatment for patients suffering from Huntington's Disease (HD).
Roche confident of closing Spark Therapeutics purchase despite facing offer extension, delay to antitrust review firstwordpharma
April 04, 2019
A Roche spokesman said Wednesday that the company remains confident that the purchase of Spark Therapeutics will be completed by the end of June, despite having to extend the offer period after only 29.4 percent of shares were tendered.
Roche to acquire gene therapy specialist Spark Therapeutics for $4.8bn pharmaceutical-technology
February 26, 2019
Roche has signed a definitive merger agreement to acquire all outstanding shares of US-based gene therapy company Spark Therapeutics for $114.50 per share....
Novartis plots 'innovative' payment models for pricey Luxturna's EU launch biospectrumasia
December 10, 2018
It’s been almost a year since Spark Therapeutics won a groundbreaking gene therapy approval in the U.S. for Luxturna, and now its marketing partner Novartis has done the same across the pond.
Spark Therapeutics Announces Updated Data on SPK-8011 from Ongoing Phase 1/2 Dose-escalation Clinical Trial in Hemophilia A at 60th American Society of Hematology (ASH) Annual Meeting and Exposition firstwordpharma
December 03, 2018
Among the five participants treated in the 2x1012 vg/kg cohort who did not experience an immune response-associated decline in FVIII expression, beginning four weeks after vector infusion, there has been a 100-percent reduction in bleeds and a greater tha
Spark Therapeutics Announces Updated Data on SPK-8011 from Ongoing Phase 1/2 Dose-escalation Clinical Trial in Hemophilia A at 60th American Society of Hematology (ASH) Annual Meeting and Exposition firstwordpharma
December 03, 2018
Among the five participants treated in the 2x1012 vg/kg cohort who did not experience an immune response-associated decline in FVIII expression, beginning four weeks after vector infusion, there has been a 100-percent reduction in bleeds and a greater tha
uniQure starts dosing in pre-pivotal hemophilia B gene therapy trial fiercebiotech
August 27, 2018
Dutch biotech uniQure has treated the first of around three patients due to enroll in its phase 2b dose-confirmation trial of hemophilia B gene therapy AMT-061.
Jazz grabs Spark’s priority review voucher for $110M fiercebiotech
May 02, 2018
Spark Therapeutics agreed to sell its priority review voucher, good for four months off an FDA decision date for any product...
Spark Therapeutics acquires licence to supply viral gene therapy outside US pharmaceutical-technology
January 29, 2018
Spark Therapeutics has signed a licensing and supply agreement with Novartis Pharmaceuticals to develop and commercialise investigational gene therapy voretigene neparvovec outside the US.
Spark Therapeutics and Pfizer amend license agreement for investigational SPK-9001 in hemophilia B worldpharmanews
November 09, 2017
Spark Therapeutics (NASDAQ: ONCE) and Pfizer (NYSE: PFE) have amended their license agreement for hemophilia B's investigational gene therapy, SPK-9001

Previous page 1 2 Next page